Related Experiment Videos
[Clinical evaluation of timentin in intensive care]
Abstract:
16 patients admitted to a MICU were treated with timentin (ticarcillin + clavulanic acid) for bacterial infections: 11 cases of pulmonary infection, 3 cases of urinary tract infection, 2 septic shocks, 3 septicemias and 1 case of multifocal infection. The pathogens considered as a firmly established cause of infection were: 5 Acinetobacter, 12 Pseudomonas, 3 Serratia, 4 Klebsiella, 1 E. coli, 2 Proteus, 1 Providencia, 1 Staphylococcus aureus, 1 Staphylococcus epidermidis, 1 Streptococcus D and 1 Flavobacterium meningosepticum. The susceptibility of these pathogens to ticarcillin and timentin is reported. Timentin was prescribed alone in 9 cases and associated (with an aminoglycoside) in 7, in a daily dose of 9 to 18 g, for 6 to 45 days. 3 patients died. The value of timentin in infections due to multiresistant MICU pathogens is stressed.
Insights
Timentin effectively treated bacterial infections in 16 MICU patients, including multidrug-resistant pathogens like Pseudomonas and Acinetobacter. This study highlights timentin
Area of Science:
- Infectious Diseases
- Pharmacology
- Critical Care Medicine
Context:
- Critically ill patients in Medical Intensive Care Units (MICUs) are susceptible to severe bacterial infections.
- Multidrug-resistant organisms (MDROs) pose a significant challenge in MICU settings.
- Timentin (ticarcillin + clavulanic acid) is an antibiotic combination used to treat bacterial infections.
Purpose:
- To evaluate the efficacy and safety of timentin in treating bacterial infections in MICU patients.
- To identify the spectrum of pathogens causing infections in this patient cohort.
- To assess the susceptibility of these pathogens to timentin.
Summary:
- Sixteen MICU patients received timentin for various bacterial infections, including pulmonary, urinary tract, septic shock, septicemia, and multifocal infections.
- Common pathogens identified were Pseudomonas (12), Acinetobacter (5), Serratia (3), and Klebsiella (4), among others.
- Timentin was administered alone or with an aminoglycoside, with susceptibility data reported for the isolated pathogens. Three patients died during the study period.
Impact:
- Timentin demonstrated value in managing infections caused by multiresistant MICU pathogens.
- The findings contribute to understanding antibiotic options for severe infections in critically ill patients.
- Further research may explore optimal dosing and combination therapies for timentin in specific MICU pathogen profiles.